{"id":"NCT04633226","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)","officialTitle":"A Phase 3, Single-Arm, Open-label Clinical Study to Evaluate the Safety and Immunogenicity of 4 Doses of V114 Administered to Healthy Infants in South Korea.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-02-10","primaryCompletion":"2022-11-04","completion":"2022-11-04","firstPosted":"2020-11-18","resultsPosted":"2024-04-15","lastUpdate":"2024-09-24"},"enrollment":58,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Disease"],"interventions":[{"type":"BIOLOGICAL","name":"V114","otherNames":["VAXNEUVANCE™","Pneumococcal 15-Valent Conjugate Vaccine"]}],"arms":[{"label":"V114","type":"EXPERIMENTAL"}],"summary":"The primary purpose of this phase 3, single-arm, open-label study is to evaluate the safety and immunogenicity of a 4-dose regimen of V114 administered to healthy infants in South Korea.","primaryOutcome":{"measure":"Percentage of Participants With ≥1 Solicited Injection-site Adverse Events","timeFrame":"Up to 7 days after any vaccination, up to a total of ~ 13 months","effectByArm":[{"arm":"V114","deltaMin":54.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":13},"locations":{"siteCount":19,"countries":["South Korea"]},"refs":{"pmids":["38497448"],"seeAlso":["https://www.merckclinicaltrials.com","https://msd.trialsummaries.com/Study/StudyDetails?id=26088&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":57},"commonTop":["Irritability","Somnolence","Decreased appetite","Injection site swelling","Injection site induration"]}}